Sun Pharmaceutical Industries Ltd. News and Updates

Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Sharekhan and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: Sharekhan

Keep track of all breaking news on Sun Pharmaceutical Industries Ltd. from all sources in a single place.

Load latest

Sun Pharmaceutical Industries Ltd.

26 Jul 2024

1655.80

1.48%

Sun Pharma hits all time high on US FDA nod for alopecia drug 'Leqselvi'

Business Standard

This came after Sun Pharmaceuticals announced that the US Food and Drug Administration (USFDA) has approved its new drug application for Deuruxolitinib, a new treatment for Alopecia Areata

Sun Pharmaceutical Industries Ltd. is trading above its 100 day SMA of 1653.1

Sun Pharma receives US FDA approval for drug to treat alopecia areata

Business Standard | 26 Jul 2024

Sun Pharmaceutical Industries Ltd.

08 Jul 2024, 07:00PM

1655.80

1.48%

Open to inorganic opportunities in specialty drugs, says Sun Pharma

Business Standard

Sun Pharma has net cash position of $2.4 bn at end of FY24; 6 new specialty products in R&D pipeline

Sun Pharmaceutical Industries Ltd.'s price crossed below 100Day SMA today

Sun Pharmaceutical Industries Ltd.

04 Jul 2024

1655.80

1.48%

USFDA pulls up Sun Pharma for manufacturing issues at Dadra facility

Business Standard

Sun Pharma failed to adequately clean and maintain equipment used for drug manufacturing at its Dadra-based manufacturing plant, as per the US Food and Drug Administration (USFDA). In a warning letter issued to company's Managing Director Dilip Shanghvi on June 18, the US health regulator stated it inspected the plant in the Union Territory of Dadra and Nagar Haveli and Daman and Diu from December 4-15, 2023. "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitise and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the USFDA said. The warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility, it stated. USFDA further noted that the company's investigations

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

24 Jun 2024

1655.80

1.48%

Sun Pharma Finalises Acquisition Of Taro For $347.73 Million

NDTV Profit

Taro has become a privately held company and is now a wholly owned subsidiary of Sun Pharma.

Sun Pharmaceutical Industries Ltd. is trading above its 100 day SMA of 1653.1

Sun Pharmaceutical Industries Ltd.

24 Jun 2024

1655.80

1.48%

Outperformance of private sector banks may continue for next one year: Sandip Sabharwal

Economic Times

The smaller pharma companies I find it tough to evaluate, so many of them can potentially do well but I do not have the bandwidth to go molecule by molecule and evaluate those companies. But I think Sun Pharma is a decent business model, so we are just holding it for the long term.

Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr

Sun Pharmaceutical Industries Ltd.

22 Jun 2024

1655.80

1.48%

Sun Pharma's investigational weight loss drug shows promise in reducing obesity

Business Today

The study enrolled 24 obese male participants who were divided into two groups: one with a fixed dosage and the other with increasing dosages of GL0034. The drug not only led to significant weight loss but also enhanced insulin sensitivity and reduced glucose levels.

Sun Pharmaceutical Industries Ltd. is trading above its 100 day SMA of 1653.1

Sun Pharmaceutical Industries Ltd.

21 Jun 2024

1655.80

1.48%

Sun Pharma and Takeda sign agreement to introduce Voltapraz in India

Business Line

The agreement grants Sun Pharma non-exclusive patent licensing rights to market Vonoprazan tablets, available in 10 mg and 20 mg dosages, in India

Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr

Sun Pharma inks MoU with Takeda to introduce gastrointestinal drug in India

Business Standard | 21 Jun 2024

Sun Pharmaceutical Industries Ltd.

20 Jun 2024

1655.80

1.48%

Sun Pharma receives warning letter from USFDA for Dadra facility

Business Line

Letter lists violations of Current Good Manufacturing Practice regulations by the facility

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

USFDA issues warning letter to Sun Pharma's Dadra unit; stock slips 2%

Business Standard | 20 Jun 2024 1 more

Sun Pharmaceutical Industries Ltd.

20 Jun 2024

1655.80

1.48%

Dadra facility receiving WL to have no impact on the company’s financials

Buy: Sun Pharmaceutical Industr...

Target

Sharekhan

Sun Pharma’s Dadra facility received a Warning Letter for a violation of cGMP regulations, which had previously received an Official Action Indicated (OAI) status on 11th Apr’24.